(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Central Nervous System Depressants
Aretaieion University HospitalSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Central Nervous System Depressants cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vts-K Theresa Jacob, PhD, MPH | Phase 4 | BB |
ly03010 Luye Pharma Group Ltd. | Phase 1 | CC |
Paliperidone Palmitate 3-Month Formulation Luye Pharma Group Ltd. | Phase 1 | CC |
FENTANYL Aretaieion University Hospital | N/A | D |
Bxcl501 Aretaieion University Hospital | N/A | D |
LIDOCAINE Aretaieion University Hospital | N/A | D |
Same molecule, other indications
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →